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Preamble
The voluntary withdrawal of cerivastatin (Baycol) from the
U.S. market on August 8, 2001, by the manufacturer, in
agreement with the Food and Drug Administration (FDA),
has prompted concern on the part of physicians and patients
regarding the safety of the cholesterol-lowering class of drugs
called HMG CoA reductase inhibitors, more commonly
known as “statins.” This American College of Cardiology/
American Heart Association/National Heart, Lung and Blood
Institute (ACC/AHA/NHLBI) Clinical Advisory is intended
to summarize for professionals the current understanding of
statin use, focused on myopathy, and to provide updated
recommendations for the appropriate use of statins, including
cautions, contraindications, and safety monitoring for statin
therapy. Its purpose is not to discourage the appropriate use of
statins, which have life-saving potential in properly selected
patients, particularly those with established coronary heart
disease (CHD) and others at high risk for developing CHD.
Included are recent myopathy information compiled by the
FDA, information from clinical trials, and summaries from
the recently released report of the Adult Treatment Panel III
(ATP III) of the National Cholesterol Education Program
(NCEP).1
Introduction
In the literature, the general terminology used to describe
muscle toxicity is inconsistent. Therefore, for the purpose of
this document, the following terms are used as defined here:
Myopathy—a general term referring to any disease of mus-
cles; myopathies can be acquired or inherited and can occur
at birth or later in life (Source: NINDS Myopathy Page-http://
accessible.ninds.nih.gov/health_and_medical/disorders/
myopathy.htm). Myalgia—muscle ache or weakness without
creatine kinase (CK) elevation. Myositis—muscle symptoms
with increased CK levels. Rhabdomyolysis—muscle symp-
toms with marked CK elevation (typically substantially
greater than 10 times the upper limit of normal [ULN]) and
with creatinine elevation (usually with brown urine and
urinary myoglobin).
Statins are powerful low-density lipoprotein (LDL)-
lowering drugs that are widely used in clinical practice.
Results from clinical trials with a mean duration of 5.4 years
have demonstrated a decrease in CHD and total mortality,
reductions in myocardial infarctions, revascularization proce-
dures, stroke, and peripheral vascular disease.2–8 These trials
documented a benefit in both men and women, primarily in
middle-aged and older persons treated in the setting of either
primary or secondary prevention. More than 50,000 individ-
uals have been randomized to either a placebo or statin in
these trials, and no serious morbidity or increase in mortality
was observed in the drug treatment groups. These agents
reduce the risk of essentially every clinical manifestation of
the atherosclerotic process; they are easy to administer, with
good patient acceptance. There are very few drug to drug
interactions. Although the experience with the safety of statin
therapy outside of clinical trials has not been fully reported, it
is reasonable to suspect that the incidence of side effects may
be higher in clinical situations where patients are not moni-
tored as closely as they are in clinical trials.9
The NCEP has published updated guidelines for treatment
of high blood cholesterol (Adult Treatment Panel III report).1
These guidelines are endorsed by the ACC and AHA. They
identify elevated LDL cholesterol as the primary target of
therapy and establish goals for LDL cholesterol that depend
on a patient’s risk status. The Adult Treatment Panel III
report was able to apply rigorous clinical trial evidence to
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identify additional high-risk individuals for treatment, greatly
expanding the number of patients who are candidates for
these drugs. These include patients with established CHD,
other forms of atherosclerotic disease, diabetes mellitus,
multiple risk factors imparting high risk, and severe hyper-
cholesterolemia. In many patients, relatively high doses of
statins will be required to achieve LDL cholesterol goals of
therapy. In addition, for patients with high triglycerides,
non– high-density lipoprotein (HDL) cholesterol
(LDLVLDL [very low density lipoprotein] cholesterol) has
been identified as a secondary target of therapy. To achieve
the non–HDL cholesterol goal, many patients will require
statin therapy as well. This broad expansion of statin use will
require that increased attention be given to every aspect of
statin therapy (i.e., efficacy, safety, and cost-effectiveness).
In view of the demonstrated safety of these agents, both
medical professionals and the public were surprised by the
recent withdrawal of a relatively new statin, cerivastatin
(Baycol), from the market. Cerivastatin was first approved for
use in the U.S. in 1997. In August 2001, the manufacturer,
Bayer AG, announced the withdrawal of all dosages of its
cholesterol-lowering drug with the brand names Baycol/
Lipobay (cerivastatin) because of increasingly frequent re-
ports of serious myopathy, including severe and life-
threatening rhabdomyolysis. Rhabdomyolysis was reported
most frequently when cerivastatin was used at higher doses
and, particularly, in combination with another lipid-lowering
drug, gemfibrozil (LOPID and generics). At the time of
withdrawal, the FDA had received reports of 31 U.S. deaths
due to severe rhabdomyolysis associated with the use of
cerivastatin, 12 of which involved concomitant gemfibrozil
use (http://www.fda.gov/cder/drug/infopage/baycol/). Subse-
quently, the Wall Street Journal (1/21/02, pg. A10) reported
that Bayer AG had indicated that as many as 100 deaths have
been linked to Baycol. The FDA reports that the rate of fatal
rhabdomyolysis is 16 to 80 times more frequent for cerivas-
tatin as compared to any other statin.10
Incidence of Adverse Events
The statins are well tolerated by most persons. Elevated
hepatic transaminases generally occur in 0.5% to 2.0% of
cases and are dose-dependent.11,12 Whether transaminase
elevation with statin therapy constitutes true hepatotoxicity
has not been determined. Progression to liver failure specif-
ically due to statins is exceedingly rare if it ever occurs.13
Reversal of transaminase elevation is frequently noted with a
reduction in dose, and elevations do not often recur with
either re-challenge or selection of another statin.14,15 Cho-
lestasis and active liver disease are listed as contraindications
to statin use; however, no specific evidence exists showing
exacerbation of liver disease by statins. Furthermore, statins
have not been shown to worsen the outcome in persons with
chronic transaminase elevations due to hepatitis B or C, and
treatment of hyperlipidemia may actually improve transami-
nase elevations in individuals with fatty liver.16 An observa-
tional study16a has suggested a rare association of statin use
with polyneuropathy. This has not been found in the large
blinded randomized controlled trials.
The ability of statins to produce myopathy under some
circumstances is well established. A common complaint is
non-specific muscle aches or joint pains that are generally not
associated with significant increases in creatine kinase. In
placebo-controlled trials, the incidence of these complaints
(generally reported as about 5%) is similar between placebo
and active drug therapy, suggesting they may not be drug-
related.12–17 Nonetheless, in some patients, the temporal
association with statin therapy is strong enough to implicate
these drugs as a cause of these complaints. Other patients can
have mild-to-moderate elevations of creatine kinase without
muscle complaints. Again, elevations may be non-specific,
but a statin effect often cannot be ruled out.
It is rare that patients treated with a statin exhibit severe
myositis characterized by muscle aches, soreness or weakness
and associated with elevated creatine kinase levels, generally
greater than 10 times the ULN. In this setting, failure to
discontinue drug therapy can lead to rhabdomyolysis, myo-
globinuria, and acute renal necrosis.18 Myositis is most likely
to occur in persons who have complex medical problems
and/or who are taking multiple medications. It may rarely
occur with statin monotherapy, but it occurs more frequently
when statins are used in combination with a variety of
medications, including cyclosporine, fibrates, macrolide an-
tibiotics, certain antifungal drugs, and niacin.19–21 Some of
the drug to drug interactions involve specific interactions
with the cytochrome P-450 drug-metabolizing system, espe-
cially those involving the 3A4 isozyme.22,23 The combination
of statins with a fibrate is attractive for persons who have both
high serum cholesterol and high triglycerides or for those
who continue to have elevated triglycerides after reaching
their LDL-cholesterol target on statin therapy. However,
there may be a concern about an increased danger of
developing myopathy with this combination. In the past, this
combination was thought to be “contraindicated” because of
the potential danger of myopathy. More recently, it has been
used increasingly with apparent safety in the majority of
persons. This combination is now presented by the ATP III
report as an option, with careful monitoring, for some forms
of dyslipidemia.
The FDA report comparing the rate of fatal rhabdomyolsis
among different statins is of considerable importance.10 The
FDA performed a detailed review of all reports of fatal
rhabdomyolysis in their Adverse Event Reporting System and
obtained the number of prescriptions dispensed since market-
ing of each statin began in the U.S. Fatal rhabdomyolysis was
extremely rare (less than 1 death/million prescriptions). As
previously noted, the rate of fatal rhabdomyolsis for cerivas-
tatin was far greater than that for other statins (16 to 80 times
higher). Even after excluding cases in which cerivastatin was
administered with gemfibrozil, the reporting rate for fatal
rhabdomyolysis with cerivastatin monotherapy (1.9 deaths
per million prescriptions) was 10 to 50 times higher than for
other statins. The FDA report also noted that more than 60%
of the fatal cases with cerivastain were associated with use of
the highest dose (0.8 mg daily). The FDA notes that the data
are reporting rates, not incidence rates. Thus, statistically
“rigorous comparisons between drugs . . . are not recom-
mended”.10 Nevertheless, review of these data strongly sug-
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gests that there were no clinically important differences in the
rate of fatal complications among the five statins now
available in the U.S. (atorvastatin, fluvastatin, lovastatin,
pravastatin, and simvastatin). Clinicians should consider the
rates of severe myopathy as equivalent among all of these
approved statins.
The following are summary comments reflecting current
experience with these issues:
● Statin therapy appears to carry a small but definite risk of
myopathy when used alone. According to several large
clinical trial databases, the incidence of severe myopathy is
reported to be 0.08% with lovastatin and simvastatin.14,15
Elevations of CK greater than 10 times the ULN have been
reported in 0.09% of persons treated with pravastatin. All
currently marketed statins appear to have a similar potential
for causing this adverse effect.
● Fibrate treatment alone appears to be associated with some
(probably similar) risk of myopathy.
● Of the nearly 600 persons who have participated in
controlled clinical trials of a statin and fibrate combination,
1% have experienced a CK greater than 3 times the ULN
without muscle symptoms, and 1% have been withdrawn
from therapy because of muscle discomfort.24–31 None of
these findings were considered serious by the trial investi-
gators. No cases of rhabdomyolysis or myoglobinuria have
been encountered in these clinical trials. The experience in
these trials is predominantly with lovastatin and gemfibro-
zil, but it is reasonable to believe that the experiences with
other statin-fibrate combinations would be similar.
Mechanism of Myopathy
Because it occurs so rarely, little is known about the funda-
mental mechanisms of statin-associated myopathy. It has
been suggested that statins lead to inhibited synthesis of
compounds arising from the synthetic pathway of cholesterol.
In theory, this could lead to ubiquinone (an essential intra-
cellular energy component) deficiency in muscle cell mito-
chondria, disturbing normal cellular respiration and causing
adverse effects including rhabdomyolysis. Despite in-vitro
support for this concept,32,33 a human study of six months of
simvastatin treatment (20 mg per day) on skeletal muscle
concentrations of high-energy phosphates and ubiquinone
demonstrated that the muscle high-energy phosphate and
ubiquinone concentrations assayed after simvastatin treat-
ment were similar to those observed at baseline and did not
differ from values in control subjects.34 No clinical study has
yet provided support for the hypothesis of diminished isopre-
noid synthesis or energy generation in muscle cells during
statin therapy. Some have proposed that statin interaction
with the cytochrome P-450 hepatic enzyme system might be
related to myopathy.22 Support for this concept comes, in
part, from the known enhanced toxicity when statins are
administered with agents sharing metabolism by the same
cytochrome isoforms. Finally, it has been shown that exercise
in combination with lovastatin produces greater creatine
kinase elevations than those produced by exercise alone,
suggesting that statins can exacerbate exercise-induced skel-
etal muscle injury.35
Diagnosis
Routine laboratory monitoring of CK is of little value in the
absence of clinical signs or symptoms. Therefore, all persons
beginning to receive statins should be instructed to report
muscle discomfort or weakness or brown urine immediately,
which should then prompt a CK measurement.
Management
Baseline Measurements
Before initiating statin therapy, baseline measurements, in-
cluding a lipid and lipoprotein profile, that will be used to
follow the drug’s efficacy and safety should be documented.
Current labeling for all statins requires baseline measure-
ments of liver function, including alanine transferase and
aspartate transferase, although this is not agreed on by many
liver experts and will likely undergo review in the future.
Modest transaminase elevations (less than 3 times the ULN)
are not thought to represent a contraindication to initiating,
continuing, or advancing statin therapy, as long as patients
are carefully monitored. Many experts also favor, and the
ATP III report recommends, baseline CK measurement,
reasoning that asymptomatic CK elevations are common and
pre-treatment knowledge of this condition can aid in later
clinical decision making.
Monitoring for Adverse Reactions and
Adjusting Therapy
Once therapy has been initiated, symptoms may appear at any
time. If myositis is present or strongly suspected, the statin
should be discontinued immediately. Several key points
should be kept in mind.
Obtain a CK measurement if the patient reports suggestive
muscle symptoms, and compare to CK blood level prior to
beginning therapy. Because hypothyroidism predisposes to
myopathy, a thyroid-stimulating hormone level should also
be obtained in any patient with muscle symptoms.
If the patient experiences muscle soreness, tenderness, or
pain, with or without CK elevations, rule out common causes
such as exercise or strenuous work. Advise moderation in
activity for persons who experience these symptoms during
combination therapy.
Discontinue statin therapy (or statin and niacin or fibrate if
the patient is on combination therapy) if a CK greater than 10
times the ULN is encountered in a patient with muscle
soreness, tenderness, or pain.
If the patient experiences muscle soreness, tenderness, or
pain with either no CK elevation or a moderate elevation (3
to 10 times the ULN), follow the patient’s symptoms and CK
levels weekly until there is no longer medical concern or
symptoms worsen to the situation described previously (at
which point therapy should be discontinued). For patients
who develop muscle discomfort and/or weakness and who
also have progressive elevations of CK on serial measure-
ments, either a reduction of statin dose or a temporary
discontinuation may be prudent. A decision can then be made
whether or when to reinstitute statin therapy.
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Asymptomatic Patients With CK Elevation
Prior to the withdrawal of cerivastatin, the ATP III report did not
recommend routine ongoing monitoring of CK in asymptomatic
patients. If a physician chooses to obtain CK values in asymp-
tomatic patients, particularly those on combination therapy, and
CKs are elevated to more than 10 times the ULN, strong
consideration should be given to stopping therapy. Following
discontinuation, wait for symptoms to resolve and CK levels to
return to normal before reinitiating therapy with either drug and
use a lower dose of the drug(s) if possible.
Some asymptomatic patients will have moderate (i.e.,
between 3 and 10 times the ULN) CK elevations at baseline,
during treatment, or after a drug holiday. Such patients can
usually be treated with a statin without harm. However,
particularly careful monitoring of symptoms and more
frequent CK measurements are indicated.
Prevention
Increased Risk States for Statin-Associated Myopathy
Prevention of statin-associated myopathy can best be ac-
complished by attention to those factors that might increase
the risk for such myopathy:
● Advanced age (especially more than 80 years) in patients
(women more than men)
● Small body frame and frailty
● Multisystem disease (e.g., chronic renal insufficiency,
especially due to diabetes)
● Multiple medications
● Perioperative periods
● Specific concomitant medications or consumption as listed
below (check specific statin package insert for warnings)
 Fibrates (especially gemfibrozil, but other fibrates too)
 Nicotinic acid (rarely)
 Cyclosporine
 Azole antifungals
 Itraconazole and ketoconazole
 Macrolide antibiotics
 Erythromycin and clarithromycin
 HIV protease inhibitors
 Nefazodone (antidepressant)
 Verapamil
 Amiodarone
 Large quantities of grapefruit juice (usually more
than 1 quart per day)
 Alcohol abuse (independently predisposes to myopathy)
Clinical Precautions
Most myopathy associated with statins appears to occur in
patients who are at risk for the condition. For this reason,
physicians should be aware of several caveats when pre-
scribing statin therapy. Myopathy is more likely to occur at
higher statin doses than at lower doses. For this reason,
doses should not exceed those required to attain the ATP III
goal of therapy. As a rule, statin therapy should be em-
ployed more cautiously in older persons, particularly older
thin or frail women, but it is not contraindicated in these or
other high-risk patients. Among older persons, those with
multisystem disease apparently are at higher risk. Patients
with diabetes combined with chronic renal failure also appear
to be at higher risk for myopathy—such patients should be
monitored carefully. In several instances, myopathy has
developed when patients were continued on statin therapy
during hospitalization for major surgery. Therefore, it prob-
ably is prudent to withhold statins during such periods.
Particular attention should be given to drug interactions
when employing statin therapy. Although the combination of
TABLE 1. Summary of HMG CoA Reductase Inhibitors
Available drugs Lovastatin, pravastatin, simvastatin,
fluvastatin, atorvastatin
Lipid/lipoprotein effects LDL cholesterol 2 18–55 percent
HDL cholesterol 1 5–15 percent
Triglycerides 2 7–30 percent
Major use To lower LDL-cholesterol
Contraindications
Absolute Active or chronic liver disease
Relative Concomitant use of cyclosporine,
gemfibrozil, or niacin, macrolide
antibiotics, various anti-fungal agents, and
cytochrome P-450 inhibitors
Efficacy Reduce risk for CHD and stroke
Safety Side effects minimal in clinical trials
Usual starting dose Lovastatin - 20 mg
Pravastatin - 20 mg
Simvastatin - 20 mg
Fluvastatin - 20 mg
Atorvastatin - 10 mg
Maximum FDA-approved
dose
Lovastatin - 80 mg
Pravastatin - 80 mg
Simvastatin - 80 mg
Fluvastatin - 80 mg
Atorvastatin - 80 mg
Available preparations Lovastatin - 10, 20, 40 mg tablets
Pravastatin - 10, 20, 40, 80 mg tablets
Simvastatin - 5, 10, 20, 40, 80 mg tablets
Fluvastatin - 20, 40, 80 (xl) mg tablets
Atorvastatin - 10, 20, 40, 80 mg tablets
TABLE 2. Monitoring Parameters and Follow-Up Schedule
Monitoring
Parameters Follow-Up Schedule
Statins Headache, dyspepsia Evaluate symptoms initially, 6 to 8
weeks after starting therapy, then
at each follow-up visit
Muscle soreness,
tenderness, or pain
Evaluate muscle symptoms and
CK before starting therapy.
Evaluate muscle symptoms 6 to
12 weeks after starting therapy
and at each follow-up visit. Obtain
a CK measurement when persons
have muscle soreness,
tenderness, or pain.
ALT, AST Evaluate ALT/AST initially,
approximately 12 weeks after
starting therapy, then annually or
more frequently if indicated.
ALTalanine transferase; and ASTaspartate transferase.
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statin plus fibrate is accompanied by an increased danger of
myopathy, the use of moderate statin doses combined with
fibrate appears to have a relatively low incidence of myop-
athy, especially when used in persons without multisystem
disease or multiple medications. The combination of statin
plus nicotinic acid seemingly carries a lower risk for myop-
athy than does statin plus fibrate. Finally, physicians should
be aware of the dangers of interactions of statins with the
other drugs previously listed. These combinations should also
be used with caution or avoided altogether. Furthermore, it is
important for clinicians prescribing statins to make sure that
their patients are aware of these potential drug interactions,
because in current practice, a patient may receive prescrip-
tions from many different caregivers.
Summary
Statin therapy holds great promise for reducing the incidence of
major coronary events, coronary procedures, and stroke in high-risk
patients. At present, this potential has not been fully realized,
because many patients at heightened risk are not being treated with
these drugs. There is a well documented under-use of statins in
clinical practice. Statins have proven to be extremely safe in the vast
majority of patients receiving them. Few significant side effects
were observed in clinical trials, and post-marketing reports of
adverse events have been very limited when considered in compar-
ison to the very large number of persons safely receiving these
drugs. Even so, these drugs are not entirely free of side effects, and
as for all drugs, they should be used appropriately and judiciously.
This advisory encourages the appropriate use of statins while
pointing out the possibility of side effects in certain patients. If
statins are used with appropriate caution in these selected patients,
the likelihood of developing clinically important myopathy should
be substantially reduced. (See Tables 1 and 2.)
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